<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/ms2025-135</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-9027</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РЕПРОДУКТИВНОЕ ЗДОРОВЬЕ И ВРТ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REPRODUCTIVE HEALTH AND ART</subject></subj-group></article-categories><title-group><article-title>Профилактика и лечение инфекционно-воспалительных осложнений у пациентов гинекологического профиля в послеоперационном периоде</article-title><trans-title-group xml:lang="en"><trans-title>Prevention and treatment of infectious and inflammatory complications in gynecological patients in the postoperative period</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2786-6181</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Доброхотова</surname><given-names>Ю. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Dobrokhotova</surname><given-names>Ju. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доброхотова Юлия Эдуардовна, д.м.н., профессор, заслуженный врач РФ, заведующая кафедрой акушерства и гинекологии лечебного факультета</p><p>117997, Москва, ул. Островитянова, д. 1</p></bio><bio xml:lang="en"><p>Julia E. Dobrokhotova, Dr. Sci. (Med.), Professor, Honoured Doctor of the Russian Federation, Head of the Department of Obstetrics and Gynecology</p><p>1, Ostrovityanov St., Moscow, 117997</p></bio><email xlink:type="simple">pr.dobrohotova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0392-8280</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маркаров</surname><given-names>A. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Markarov</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Маркаров Арнольд Эдуардович, к.м.н., главный врач</p><p>105187, Москва, ул. Фортунатовская, д. 1</p></bio><bio xml:lang="en"><p>Arnold E. Markarov, Cand. Sci. (Med.), Chief Medical Officer</p><p>1, Fortunatovskaya St., Moscow, 105187</p></bio><email xlink:type="simple">gkb36@zdrav.mos.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5660-2380</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Котомина</surname><given-names>Т. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kotomina</surname><given-names>T. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Котомина Татьяна Сергеевна, к.м.н., заместитель главного врача по акушерско-гинекологической помощи</p><p>105187, Москва, ул. Фортунатовская, д. 1</p></bio><bio xml:lang="en"><p>Tatiana S. Kotomina, Cand. Sci. (Med.), Deputy Chief Physician for Obstetrics and Gynecology Care</p><p>1, Fortunatovskaya St., Moscow, 105187</p><p> </p></bio><email xlink:type="simple">gkb36@zdrav.mos.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1554-3633</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хлынова</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Khlynova</surname><given-names>S. А.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хлынова Светлана Анатольевна, к.м.н., доцент кафедры акушерства и гинекологии лечебного факультета, Российский национальный исследовательский медицинский университет имени Н.И. Пирогова; врач акушер-гинеколог, Городская клиническая больница имени Ф.И. Иноземцева</p><p>117997, Москва, ул. Островитянова, д. 1,</p><p>105187, Москва, ул. Фортунатовская, д. 1</p></bio><bio xml:lang="en"><p>Svetlana A. Khlynova, Cand. Sci. (Med.), Associate Professor of the Department of Obstetrics and Gynecology, Faculty of General Medicine, Pirogov Russian National Research Medical University; Obstetrician-Gynecologist, Inozemtsev City Clinical Hospital of the Department of Health of Moscow</p><p>1, Ostrovityanov St., Moscow, 117997, </p><p>1, Fortunatovskaya St., Moscow, 105187</p></bio><email xlink:type="simple">doc-khlinova@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9491-9303</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маркова</surname><given-names>Э. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Markova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Маркова Элеонора Александровна, к.м.н., доцент кафедры акушерства и гинекологии лечебного факультета, Российский национальный исследовательский медицинский университет имени Н.И. Пирогова; врач акушер-гинеколог, Городская клиническая больница имени Ф.И. Иноземцева</p><p>117997, Москва, ул. Островитянова, д. 1,</p><p>105187, Москва, ул. Фортунатовская, д. 1</p></bio><bio xml:lang="en"><p>Eleonora A. Markova, Cand. Sci. (Med.), Associate Professor of the Department of Obstetrics and Gynecology, Faculty of General Medicine, Pirogov Russian National Research Medical University; Obstetrician-Gynecologist, Inozemtsev City Clinical Hospital of the Department of Health of Moscow</p><p>1, Ostrovityanov St., Moscow, 117997, </p><p>1, Fortunatovskaya St., Moscow, 105187</p></bio><email xlink:type="simple">markova.eleonora@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9279-7851</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Слюсарева</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Slyusareva</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Слюсарева Ольга Александровна, к.м.н., ассистент кафедры акушерства и гинекологии лечебного факультета, Российский национальный исследовательский медицинский университет имени Н.И. Пирогова; врач акушер-гинеколог, Городская клиническая больница имени Ф.И. Иноземцева</p><p>117997, Москва, ул. Островитянова, д. 1,</p><p>105187, Москва, ул. Фортунатовская, д. 1</p></bio><bio xml:lang="en"><p>Olga A. Slyusareva, Cand. Sci. (Med.), Assistant of the Department of Obstetrics and Gynecology, Faculty of General Medicine, Pirogov Russian National Research Medical University; Obstetrician-Gynecologist, Inozemtsev City Clinical Hospital of the Department of Health of Moscow</p><p>1, Fortunatovskaya St., Moscow, 105187,</p><p>1, Ostrovityanov St., Moscow, 117997</p></bio><email xlink:type="simple">Lelechka.86@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российский национальный исследовательский медицинский университет имени Н.И. Пирогова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Городская клиническая больница имени Ф.И. Иноземцева</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Inozemtsev City Clinical Hospital of the Department of Health of Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Российский национальный исследовательский медицинский университет имени Н.И. Пирогова;&#13;
Городская клиническая больница имени Ф.И. Иноземцева</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University;&#13;
Inozemtsev City Clinical Hospital of the Department of Health of Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>26</day><month>04</month><year>2025</year></pub-date><volume>0</volume><issue>4</issue><fpage>76</fpage><lpage>84</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Доброхотова Ю.Э., Маркаров A.Э., Котомина Т.С., Хлынова С.А., Маркова Э.А., Слюсарева О.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Доброхотова Ю.Э., Маркаров A.Э., Котомина Т.С., Хлынова С.А., Маркова Э.А., Слюсарева О.А.</copyright-holder><copyright-holder xml:lang="en">Dobrokhotova J.E., Markarov A.E., Kotomina T.S., Khlynova S.А., Markova E.A., Slyusareva O.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/9027">https://www.med-sovet.pro/jour/article/view/9027</self-uri><abstract><sec><title>Введение</title><p>Введение. В настоящее время наблюдается высокая частота нарушения микробиоценоза влагалища (85–90%) в послеоперационном периоде у пациенток с различными нозологическими формами гинекологических заболеваний, требующих оперативного лечения.</p></sec><sec><title>Цель</title><p>Цель. Изучить эффективность и переносимость препарата Депантол®, представляющего собой комбинацию антисептика и репаранта, для профилактики и лечения послеоперационных инфекционно-воспалительных осложнений нижнего отдела генитального тракта после хирургических вмешательств, выполненных вагинальным доступом.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проспективное сравнительное исследование включило 588 пациенток, перенесших оперативное вмешательство вагинальным доступом. Первую группу составили 98 пациенток, которым была проведена вагинальная гистерэктомия, пластика стенок влагалища и/или транссакроспинальная гистеропексия со стандартным ведением послеоперационного периода. Вторую группу – 236 пациенток, которым проведена вагинальная гистерэктомия и пластика стенок влагалища, в дополнение к стандартной терапии в течение 10 дней пациентки получали Депантол по 1 свече два раза в день. Третью – 254 пациентки после транссакроспинальной гистеропексии, в послеоперационном периоде получавшие Депантол® согласно инструкции по применению.</p></sec><sec><title>Результаты</title><p>Результаты. Результаты исследования продемонстрировали, что клинические симптомы, такие как гиперемия, отек, жжение, через 14 сут. после лечения отмечались у 49,9% у пациенток первой группы, у 2,1% во второй и у 1,5% в третьей, что может свидетельствовать о благоприятном влиянии препарата Депантол на процессы трофики и регенерации тканей влагалища, что подтверждается на 25% (ОШ 0,3 (ДИ: 0,11–0,71, p &lt; 0,05), ОР 0,25 (ДИ: 0,14–0,46, p &lt; 0,05)) менее выраженной гиперемией послеоперационной раны у пациенток второй и третьей группы, чем у пациенток первой группы.</p></sec><sec><title>Выводы</title><p>Выводы. Отдаленные результаты исследования позволяют рекомендовать препарат Депантол® с высокой комплаентностью, хорошей переносимостью, благоприятным профилем безопасности, соответствующий принципам FTS-активного ведения послеоперационного периода у пациентов после вагинальных оперативных вмешательств.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Currently, there is a high frequency of vaginal microbiocenosis disorders (85–90%) in the postoperative period in patients with various nosological forms of gynecological diseases requiring surgical treatment.</p></sec><sec><title>Aim</title><p>Aim. To study the efficacy and tolerability of Depantol®, a combination of an antiseptic and a reparant complex, for the prevention and treatment of postoperative infectious and inflammatory complications of the lower genital tract after surgical interventions performed through vaginal access.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. A prospective comparative study involving 588 patients who underwent vaginal surgery was designed to evaluate the efficacy of Depantol® in the prevention and treatment of infectious and inflammatory complications of the lower genital tract. The first group consisted of 98 patients who underwent vaginal hysterectomy, vaginal wall plastic surgery and/or transsacrospinal hysteropexy and standard postoperative management; the second group consisted of 236 patients who underwent vaginal hysterectomy and vaginal wall plastic surgery; in addition to standard therapy for 10 days, the patients received Depantol® 1 suppository 2 times a day for 10 days; the third – 254 patients after transsacrospinal hysteropexy, who received Depantol in the postoperative period, according to the instructions for use.</p></sec><sec><title>Results</title><p>Results. The results of the study demonstrated that clinical symptoms 14 days after treatment were observed in 49.9% of patients in the first group, 2.1% in the second, and 1.5% in the third, which may indicate a favorable effect of Depantol on the processes of trophism and regeneration of vaginal tissues, which is confirmed by 25% (OR 0.3 (CI: 0.11–0.71, p &lt; 0.05), RR 0.25 (CI: 0.14–0.46, p &lt; 0.05)) less pronounced hyperemia of the postoperative wound in patients of the second and third groups than in patients of the first group.</p></sec><sec><title>Conclusions</title><p>Conclusions. The long-term results of the study allow us to recommend Depantol, with high compliance, good tolerability, a favorable safety profile, corresponding to the principles of FTS-active management of the postoperative period in patients after vaginal surgeries, in order to accelerate recovery by optimizing rehabilitation, reducing microbial contamination of the vagina, and enhancing the epithelialization processes of the postoperative wound.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>вагинальная гистерэктомия</kwd><kwd>острый вагинит</kwd><kwd>бактериальный вагиноз</kwd><kwd>Депантол</kwd><kwd>послеоперационный период</kwd><kwd>инфекционные осложнения</kwd></kwd-group><kwd-group xml:lang="en"><kwd>vaginal hysterectomy</kwd><kwd>acute vaginitis</kwd><kwd>bacterial vaginosis</kwd><kwd>Depantol</kwd><kwd>postoperative period</kwd><kwd>infectious complications</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Noé G.K. Genital prolapse surgery: what options do we have in the age of mesh issues? J Clin Med. 2021;10(2):267. https://doi.org/10.3390/jcm10020267.</mixed-citation><mixed-citation xml:lang="en">Noé G.K. Genital prolapse surgery: what options do we have in the age of mesh issues? J Clin Med. 2021;10(2):267. https://doi.org/10.3390/jcm10020267.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Беженарь ВФ, Линде ВА, Плеханов АН (ред.). Влагалищный доступ в гинекологии. М.: ГЭОТАР-Медиа; 2024. 200 с. https://doi.org/10.33029/9704-8150-9-VIG-2024-1-200.</mixed-citation><mixed-citation xml:lang="en">Беженарь ВФ, Линде ВА, Плеханов АН (ред.). Влагалищный доступ в гинекологии. М.: ГЭОТАР-Медиа; 2024. 200 с. https://doi.org/10.33029/9704-8150-9-VIG-2024-1-200.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Maher C, Yeung E, Haya N, Christmann-Schmid C, Mowat A, Chen Z et al. Surgery for women with apical vaginal prolapse. Cochrane Database Syst Rev. 2023;7(7):CD012376. https://doi.org/10.1002/14651858.CD012376.pub2.</mixed-citation><mixed-citation xml:lang="en">Maher C, Yeung E, Haya N, Christmann-Schmid C, Mowat A, Chen Z et al. Surgery for women with apical vaginal prolapse. Cochrane Database Syst Rev. 2023;7(7):CD012376. https://doi.org/10.1002/14651858.CD012376.pub2.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Лапина ИА, Доброхотова ЮЭ, Таранов ВВ, Чирвон ТГ, Волкова П, Малахова АА. Комплексное ведение пациенток с пролапсом тазовых органов и метаболическим синдромом. Гинекология. 2021;23(3):260–266. https://doi.org/10.26442/20795696.2021.3.200962.</mixed-citation><mixed-citation xml:lang="en">Lapina IA, Dobrokhotova YE, Taranov VV, Chirvon TG, Volkova P, Malakhova AA. Comprehensive management of patients with pelvis organ prolapse and metabolic syndrome. Gynecology. 2021;23(3):260–266. (In Russ.) https://doi.org/10.26442/20795696.2021.3.200962.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Balgobin S, Balk EM, Porter AE, Misal M, Grisales T, Meriwether KV et al.; Society of Gynecologic Surgeons Systematic Review Group. Enabling Technologies for Gynecologic Vaginal Surgery: A Systematic Review. Obstet Gynecol. 2024;143(4):524–537. https://doi.org/10.1097/AOG.0000000000005522.</mixed-citation><mixed-citation xml:lang="en">Balgobin S, Balk EM, Porter AE, Misal M, Grisales T, Meriwether KV et al.; Society of Gynecologic Surgeons Systematic Review Group. Enabling Technologies for Gynecologic Vaginal Surgery: A Systematic Review. Obstet Gynecol. 2024;143(4):524–537. https://doi.org/10.1097/AOG.0000000000005522.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lowenstein L, Mor O, Matanes E, Justman N, Stuart A, Baekelandt J. Conventional vaginal approach vs. transvaginal natural orifice transluminal endoscopic surgery for treating apical prolapse, a randomized controlled study. Eur J Obstet Gynecol Reprod Biol. 2024;303:180–185. https://doi.org/10.1016/j.ejogrb.2024.10.032.</mixed-citation><mixed-citation xml:lang="en">Lowenstein L, Mor O, Matanes E, Justman N, Stuart A, Baekelandt J. Conventional vaginal approach vs. transvaginal natural orifice transluminal endoscopic surgery for treating apical prolapse, a randomized controlled study. Eur J Obstet Gynecol Reprod Biol. 2024;303:180–185. https://doi.org/10.1016/j.ejogrb.2024.10.032.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Miranne JM, Gabriel I, Cohen SL, Abdalian T, Ajao MO, Minassian VA. Oxycodone Use During the Postoperative Period After Hysterectomy for Benign Indications. Female Pelvic Med Reconstr Surg. 2022;28(2):90–95. https://doi.org/10.1097/SPV.0000000000001084.</mixed-citation><mixed-citation xml:lang="en">Miranne JM, Gabriel I, Cohen SL, Abdalian T, Ajao MO, Minassian VA. Oxycodone Use During the Postoperative Period After Hysterectomy for Benign Indications. Female Pelvic Med Reconstr Surg. 2022;28(2):90–95. https://doi.org/10.1097/SPV.0000000000001084.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Худолей ЕП, Ищенко АИ, Александров ЛС, Ищенко АА. Применение принципов fast track хирургии в лечении тазового пролапса. Архив акушерства и гинекологии им. В.Ф. Снегирева. 2019;6(2):98–102. https://doi.org/10.18821/2313-8726-2019-6-2-98-102.</mixed-citation><mixed-citation xml:lang="en">Khudoley EP, Ishchenko AI, Aleksandrov LS, Ishchenko AA. Application of the fast track principles of surgery in the treatment of a paz prolapse. V.F. Snegirev Archives of Obstetrics and Gynecology. 2019;6(2):98–102. (In Russ.) https://doi.org/10.18821/2313-8726-2019-6-2-98-102.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Волков ОА, Шрамко СВ, Марченко ЕЕ, Карапетян АЖ, Власенко АЕ. Влияние технологии ускоренного восстановления на результаты лапароскопических негистерэктомических операций. Акушерство и гинекология. 2024;(9):99–107. https://doi.org/10.18565/aig.2024.155.</mixed-citation><mixed-citation xml:lang="en">Volkov OA, Shramko SV, Marchenko EE, Karapetyan AJ, Vlasenko AE. The impact of Fast Track Surgery technology on the outcomes of laparoscopic non-hysterectomy interventions. Akusherstvo i Ginekologiya (Russian Federation). 2024;(9):99–107. (In Russ.) https://doi.org/10.18565/aig.2024.155.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Доброхотова ЮЭ, Лапина ИА, Тян АГ, Таранов ВВ, Чирвон ТГ, Глебов НВ, Кайкова ОВ. Профилактика инфекционных осложнений после операции по поводу пролапса гениталий. Акушерство и гинекология. 2024;(4):139–146. https://doi.org/10.18565/aig.2024.70.</mixed-citation><mixed-citation xml:lang="en">Dobrokhotova YuE, Lapina IA, Tyan AG, Taranov VV, Chirvon TG, Glebov NV, Kaykova OV. Prevention of infectious complications after genital prolapse surgery. Akusherstvo i Ginekologiya (Russian Federation). 2024;(4):139–146. (In Russ.) https://doi.org/10.18565/aig.2024.70.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nowakowski Ł, Gałczyński K, Dybowski M, Typek R, Dawidowicz A, Miotła P, Olcha P, Rechberger T. Effects of topical dehydroepiandrosterone therapy in women after pelvic organ prolapse surgery. Menopause. 2023;30(6):629–634. https://doi.org/10.1097/GME.0000000000002183.</mixed-citation><mixed-citation xml:lang="en">Nowakowski Ł, Gałczyński K, Dybowski M, Typek R, Dawidowicz A, Miotła P, Olcha P, Rechberger T. Effects of topical dehydroepiandrosterone therapy in women after pelvic organ prolapse surgery. Menopause. 2023;30(6):629–634. https://doi.org/10.1097/GME.0000000000002183.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Søgaard NB, Glavind K. Complications and re-operations after tension-free vaginal tape operation in women with stress urinary incontinence. Int Urogynecol J. 2021;32(1):159–166. https://doi.org/10.1007/s00192-020-04402-5.</mixed-citation><mixed-citation xml:lang="en">Søgaard NB, Glavind K. Complications and re-operations after tension-free vaginal tape operation in women with stress urinary incontinence. Int Urogynecol J. 2021;32(1):159–166. https://doi.org/10.1007/s00192-020-04402-5.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lundmark Drca A, Alexandridis V, Andrada Hamer M, Teleman P, Söderberg MW, Ek M. Dyspareunia and pelvic pain: comparison of midurethral sling methods 10 years after insertion. Int Urogynecol J. 2024;35(1):43–50. https://doi.org/10.1007/s00192-023-05585-3.</mixed-citation><mixed-citation xml:lang="en">Lundmark Drca A, Alexandridis V, Andrada Hamer M, Teleman P, Söderberg MW, Ek M. Dyspareunia and pelvic pain: comparison of midurethral sling methods 10 years after insertion. Int Urogynecol J. 2024;35(1):43–50. https://doi.org/10.1007/s00192-023-05585-3.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Daly JO, Frazer M, Cartwright R, Veit-Rubin N, Giles M. The role of microbial colonisation and infection in pelvic floor mesh complications and implications for management: a commentary. BJOG. 2020;127(2):260–263. https://doi.org/10.1111/1471-0528.15965.</mixed-citation><mixed-citation xml:lang="en">Daly JO, Frazer M, Cartwright R, Veit-Rubin N, Giles M. The role of microbial colonisation and infection in pelvic floor mesh complications and implications for management: a commentary. BJOG. 2020;127(2):260–263. https://doi.org/10.1111/1471-0528.15965.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Манухин ИБ, Манухина ЕИ, Сафарян ИР. Санация влагалища как способ профилактики послеоперационных осложнений у пациенток с различной гинекологической патологией. РМЖ. Мать и дитя. 2021;4(4):322–327. https://doi.org/10.32364/2618-8430-2021-4-4-322-327.</mixed-citation><mixed-citation xml:lang="en">Manukhin IB, Manukhina EI, Safaryan IR. Vaginal hygiene to prevent postoperative complications in various gynecological diseases. Russian Journal of Woman and Child Health. 2021;4(4):322–327. (In Russ.) https://doi.org/10.32364/2618-8430-2021-4-4-322-327.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ciarolla AA, Lapin N, Williams D, Chopra R, Greenberg DE. Physical approaches to prevent and treat bacterial biofilm. Antibiotics. 2022;12(1):54. https://doi.org/10.3390/antibiotics12010054.</mixed-citation><mixed-citation xml:lang="en">Ciarolla AA, Lapin N, Williams D, Chopra R, Greenberg DE. Physical approaches to prevent and treat bacterial biofilm. Antibiotics. 2022;12(1):54. https://doi.org/10.3390/antibiotics12010054.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Harris JB, Monir RL, Schoch JJ. Chlorhexidine gluconate for antisepsis in preterm neonates: A review of safety and efficacy. Pediatr Dermatol. 2024;41(5):786–792. https://doi.org/10.1111/pde.15709.</mixed-citation><mixed-citation xml:lang="en">Harris JB, Monir RL, Schoch JJ. Chlorhexidine gluconate for antisepsis in preterm neonates: A review of safety and efficacy. Pediatr Dermatol. 2024;41(5):786–792. https://doi.org/10.1111/pde.15709.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Шалепо КВ, Спасибова ЕВ, Будиловская ОВ, Крысанова АА, Хуснутдинова ТА, Чеберя АС и др. Оценка эффективности in vitro компонентов препарата «Депантол» против биопленок, сформированных вагинальными микроорганизмами. Акушерство и гинекология. 2024;(10):158–166. https://doi.org/10.18565/aig.2024.256.</mixed-citation><mixed-citation xml:lang="en">Shalepo KV, Spasibova EV, Budilovskaya OV, Krysanova AA, Khusnutdinova TA, Cheberya AS et al. Evaluation of the in vitro effectiveness of the Depantol components on biofilms produced by vaginal microorganisms. Akusherstvo i Ginekologiya (Russian Federation). 2024;(10):158–166. (In Russ.) https://doi.org/10.18565/aig.2024.256.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Назарова НМ, Некрасова МЕ, Довлетханова ЭР, Абакарова ПР. Вагиниты и цервициты: выбор эффективного метода терапии (обзор литературы). Медицинский совет. 2020;(3):17–23. https://doi.org/10.21518/2079-701X-2020-3-17-23.</mixed-citation><mixed-citation xml:lang="en">Nazarova NM, Nekrasova ME, Dovletkhanova ER, Abakarova PR. Vaginitis and cervicitis: choice of an effective therapy method (literature review). Meditsinskiy Sovet. 2020;(3):17–23. (In Russ.) https://doi.org/10.21518/2079-701X-2020-3-17-23.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Радзинский ВЕ, Хамошина МБ, Оразов МР, Тулупова МС, Пестрикова ТЮ, Ярмолинская МИ, Рымашевский АН. Результаты многоцентрового наблюдательного исследования: терапия острого вагинита неспецифи ческой и смешанной этиологии у пациенток репродуктивного возраста. Акушерство и гинекология. 2019;(8):150–158. https://doi.org/10.18565/aig.2019.8.150-158.</mixed-citation><mixed-citation xml:lang="en">Radzinskiy VE, Khamoshina MB, Orazov MR, Tulupova MS, Pestrikova TYu, Yarmolinskaya MI, Rymashevsky AN. Results of a multicenter observational study: therapy for acute non-specific and mixed vaginitis in reproductiveaged patients. Akusherstvo i Ginekologiya (Russian Federation). 2019;(8):150–158. (In Russ.) https://doi.org/10.18565/aig.2019.8.150-158.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Лапина ИА, Доброхотова ЮЭ, Таранов ВВ, Чирвон ТГ. Профилактика дисбиотических и воспалительных заболеваний влагалища и вульвы после хирургической коррекции генитального пролапса и стрессового недержания мочи. Гинекология. 2020;22(6):111–114. https://doi.org/10.26442/20795696.2020.6.200547.</mixed-citation><mixed-citation xml:lang="en">Lapina IA, Dobrokhotova JE, Taranov VV, Chirvon TG. Prevention of dysbiotic and inflammatory diseases of the vagina and vulva after surgical correction of genital prolapse and stress urinary incontinence. Gynecology. 2020;22(6): 111–114. (In Russ.) https://doi.org/10.26442/20795696.2020.6.200547.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Daly JO, Frazer M, Cartwright R, Veit-Rubin N, Giles M. The role of microbial colonisation and infection in pelvic floor mesh complications and implications for management: a commentary. BJOG. 2020;127(2):260–263. https://doi.org/10.1111/1471-0528.15965.</mixed-citation><mixed-citation xml:lang="en">Daly JO, Frazer M, Cartwright R, Veit-Rubin N, Giles M. The role of microbial colonisation and infection in pelvic floor mesh complications and implications for management: a commentary. BJOG. 2020;127(2):260–263. https://doi.org/10.1111/1471-0528.15965.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Баринова ЭК, Арютин ДГ, Ордиянц ЕГ, Ордиянц ИМ, Зулумян ТН, Камарова ЗН. Mesh-ассоциированные осложнения в гинекологии. Акушерство и гинекология: новости, мнения, обучение. 2021;9(3):102–107. https://doi.org/10.33029/2303-9698-2021-9-3suppL-102-107.</mixed-citation><mixed-citation xml:lang="en">Barinova EK, Aryutin DG, Ordiyants EG, Ordiyants IM, Zulumyan TN, Kamarova ZN. Mesh-associated complications in gynecology. Akusherstvo i Ginekologiya: Novosti, Mneniya, Obuchenie. 2021;9(3):102–107. (In Russ.) https://doi.org/10.33029/2303-9698-2021-9-3supp1-102-107.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Савичева АМ, Спасибова ЕВ, Шалепо КВ. Исследование чувствительности клинических изолятов микроорганизмов, выделенных из урогенитального тракта женщин, к действующим веществам, входящим в состав препарата Депантол. Российский вестник акушера-гинеколога. 2019;19(1):86–91. https://doi.org/10.17116/rosakush20191901192.</mixed-citation><mixed-citation xml:lang="en">Savicheva AM, Spasibova EV, Shalepo KV. Investigation of the susceptibility of clinical microbial isolates from the female urogenital tract to the active ingredients contained in Depanthol. Russian Bulletin of Obstetrician-Gynecologist. 2019;19(1):86–91. (In Russ.) https://doi.org/10.17116/rosakush20191901192.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
